Verizon Communications (VZ) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Jefferies Reiterates Buy Following Verizon Communications (VZ) 3Q Results
October 21, 2015 9:04 AM EDTJefferies reiterated a Buy rating and $53.00 price target on Verizon Communications (NYSE: VZ) following the company's 3Q15 earnings results.
Analyst Mike McCormack commented, "Results reflected better profitability in both Wireless and Wireline. Wireless continues to perform well in a challenging environment, evident in... More
Cowen Reiterates Market Perform as Verizon Communications (VZ) Reports In-Line Results
October 21, 2015 6:55 AM EDTCowen reiterated a Market Perform rating and $48.00 price target on Verizon Communications (NYSE: VZ) following the company's 3Q15 earnings results. VZ reported mostly in line 3Q15 results including rev/EPS of $33.16B/$1.04 vs. the Streets $32.97B/$1.02E.
Analyst Colby Synesael commented, "VZ... More
Wall Street ends down with healthcare, IBM; United Tech rises
October 20, 2015 7:13 AM EDTBy Caroline Valetkevitch
(Reuters) - U.S. stocks ended slightly lower on Tuesday as a decline in healthcare and biotech stocks offset gains in United Technologies and Verizon.
A 5.7 percent drop to $140.64 in IBM (NYSE: IBM) also weighed on the market. The stock hit a five-year intraday low at $140.28 after it reported a bigger-than-expected decline in quarterly revenue and cut its full-year profit forecast.
The S&P healthcare sector fell 1.5 percent, while the Nasdaq Biotech Index dropped 3.2 percent. Concerns about drug pricing have hit biotech and other healthcare shares.
... More